TrialSiteNews

Dr. Nick Gravenstein and Cyndi Garvan, PhD with the University of Floridapresent the use of adenosinefor the treatment of ARDS caused by COVID-19. Led by Dr. Bruce Spiess,the “Arctic Team at University of Florida investigates adenosine, a ubiquitous molecule with all kinds of important impacts. It actually can interfere with some viral entry into cells. Normally it's used to treat cardiac arrhythmias (intravenously) but the team from Florida think there could be a potential COVID-19 repurpose use case for the already approved drug. For example it has shown antiviral qualities. Watch the event sponsored by Steve Kirsch and the COVID-19 Early Treatment Fund (CETF).

TrialSite News productions introduces a new documentary special about Peru, COVID-19, and the acceptance of Ivermectin as a formally approved treatment for the novel coronavirus. Filmed right in Peru by a Peruvian film crew contracted by TrialSite, the documentary was commissioned to help other parts of the world better understand why Peru and the surrounding region have become an epicenter for a community physician movement that advocated for the off-label use of Ivermectin to treat COVID-19 patients. Many doctors there in the South American nation swear by it. In fact, some of them cursed the government for not embracing it sooner while other doctors are vehemently opposed to the use of the anti-parasitic drug for COVID-19—at least until there is more actual evidence of its efficacy. Watch this original TrialSite production to learn how Ivermectin became popular in Peru as an Ivermectin treatment. What is the basis and justification for its use? Have formal clinical trials been undertaken there? Why are many physicians fervently pro-use while others adamantly opposed? What is going on with self-treatment and why does that represent trouble in Peru? What is the path forward for Ivermectin as a COVID-19 treatment in Peru? This South American country might just portend the future for other low-to-middle-income countries as they seek pragmatic ways to battle the novel coronavirus.

In “Hemoperfusion to Treat Severe COVID-19” Keith R. McCrea, PhD and Robert S. Ward, NAE CEO and President of the ExThera Medical Corporation report that their process is already approved in Europe and authorized under emergency use in the United States by the Food and Drug Administration (FDA). Dr. McCrea shares what he considers a “little different” approach, involving both the purification and the actual physical removal of the pathogen from the blood. The company was indeed granted an EUA on April 17, 2020. Watch the event sponsored by Steve Kirsch and the COVID-19 Early Treatment Fund (CETF).

Steve Kirsch, founder of the COVID-19 Early Treatment Fund (CETF) discussed the evidence backing fluvoxamine as a treatment for COVID-19.

The ivermectin situation continues in controversy as a new French civic group known as the BonSens Association makesallegationsof scientific misconduct associated with the ivermectin meta-analysisauthored by Dr. Andrew Hill and a group of researchers affiliated with the University of Liverpool and Unitaid. TrialSite has gained insight on this imbroglio from a series of conversations with relevant and associated parties, some that wish to remain anonymous that have shared that in fact this study was modified separate and apart from the investigator. According to some ivermectin proponents, at stake here is more than just issues of scientific integrity but importantly, the health of hundreds of millions of people and the operation of free markets, which depend on the rule of law, scientific transparency, and rational actions by government health authorities and regulatory bodies. On the other hand, the overwhelming consensus among research institutes, regulatory entities and academic medical centers not to mention international health bodies such as the World Health Organization (WHO) declare emphatically the need for large randomized controlled trials.Dr. Hill, a well-respected researcher andadvocate for economical treatments for COVID-19, is resolute and stands behind the study.

TrialSite hosted a panel of experts for an informative and lively discussion about the Covid-19 pandemic in Canada, the governments response to it and the path forward for Canadians and the world in general. The webinar was very well attended with an oversubscribed audience also watching live on Facebook.

Article 1 |BIRD—Evidence to Decision Framework Meeting for Ivermectin’s Efficacy The British Ivermectin Recommendation Development (BIRD) panel included dozens of multinational scientists and doctors discussing the mounting data points and evidence supporting the use of Ivermectin for COVID-19 cases. The large, diverse group reviewed the evidence associated with ivermectin to potentially prevent and treat COVID-19, with a goal of reaching a consensus and making recommendations for further investigation and/or use. Article 2 | Sheba Medical Center Affiliated Principal Investigator Discusses the Successful Ivermectin Study for Mild COVID-19 Professor Eli Schwarz, the Director of the Center for Geographic Medicine at Sheba Medical Center in Tel-Hashomer, Israel, reported on the success of a randomly controlled, double-blind clinical trial showing that the generic drug ivermectin materially reduces COVID-19 viral shedding. His study, well designed and conducted in one of the top health centers in the world, reveals that, in fact, ivermectin does reduce viral shedding overall in patients with COVID-19. Although the patient sample was not sufficiently sized, the data findings supports that the off-label FDA-approved drug can reduce infectivity duration.

A lively discussion from the DarkHorse Podcast with Bret Weinstein - about vaccine technology, safety and policy. This was first posted on YouTube where it received hundreds of thousands of views, and was subsequently deleted by YouTube. Speakers: Robert Malone - the inventor of mRNA technology Steve Kirsch - Executive Director of Covid-19 Early Treatment Fund Bret Weinstein - host of the DarkHorse Podcast Timestamps: 00:00Introductions 02:20This must be discussed 03:13Will herd immunity be reached? 07:58Spike protein is very dangerous 13:45FDA knew it could be toxic if it didn't stay stuck 18:09Vaccine sufferers censored 23:26Reviewing the FDA data package 26:41Corners were cut 27:52Steve looking at VAERS 32:37Robert's friends at the FDA and the emergency use authorization 37:38Risk benefit and quality life years 40:18Alternative to vaccines 44:19Mask wearing RCT 45:28Three anomalies around vaccines 46:05Fluvoxamine trials 51:00Two million dollar offer and the NIH 52:13Robert's view of the NIH 53:00Regulatory capture 54:41Fauci's emails 56:30Merck on Ivermectin 59:24Emergent phenomenon 01:01:42Vaccine deaths 01:03:24Tess Lawrie's vaccine safety data 01:04:43Difference between the gene therapy vaccines 01:06:40Self reported deaths from vaccines 01:09:18Adverse reactions 01:17:12Robert on V-safe database 01:19:30Social media censorship 01:22:20Steve's experience with denial 01:24:17Two teams 01:28:20"Don't come back until your lips are blue" 01:30:52"Treat people early with drugs" 01:32:11Ignoring frontline doctors 01:35:39Financial incentives 01:37:28Response to demand for RCT on ivermectin 01:38:39Robert's personal experience with repurposing drugs 01:40:52Mink and ferrets lab research 01:43:53Robert on animal model for COVID treatment 01:46:33Ivermectin works 01:49:13Repurposing drugs 01:52:17Doctors ignoring treatments 01:55:31Effective treatments for long haulers 01:56:45Robert's response on incentives and hospital liability 02:01:42Additional antiviral and Gilead overlooking it 02:03:13Communication is forbidden Find Bret Weinstein on Twitter:@BretWeinstein

Article 1| Italian-led Ivermectin Meta-Analysis: Is it Time to Consider the Generic Low Cost Option to Help Treat COVID-19? A group of six critical care physicians and researchers, four of who are affiliated with IRCCS (IRCCS Ospedale San Raffaele) San Raffaele Scientific Institute in Milan, Italy, recently conducted a meta-analysis looking into ivermectin and along the way asking a highly uncomfortable question as to whether suspect claims about safety for commonly available drugs in fact are driven by a deep-seated, intensive fear of failure among the scientific and medical community. The idea that, with tens of billions have been invested into a particular approach, anything that gets in the way could be deemed recognition of failure. Article 2 | Emory Discovered Drug May Take Over $3+ Billion Market Now Going to Remdesivir EIDD-2801, the Merck drug now known as Molnupiravir, can be administered orally as a pill in an outpatient setting. Now, as we have identified here at TrialSite News, The big gap drug companies have yet to fill with regards to COVID-19 is treatment at early onset of the SARS-CoV-2 virus, during the mild to moderate stage. Instead, what most commonly happens today, is folks diagnosed positive are often simply sent home most of the time with no treatment.

Article 1 | Did the López-Medina Study in Cali Colombia Ivermectin Trial Include Protocol Deviations and 38 Switched Ivermectin and Placebo Doses? Why did the mainstream media (e.g. CNN and New York Times) also pounce so fast on the story when so many positive trials have gone by without any interest? Critics of the positive result studies involving ivermectin have tossed indiscriminate criticism involving study design and study quality. Not surprisingly, none of the issues or concerns, including potential conflict of interest with direct pharmaceutical industry payments during the study raise even a word. And what about protocol violations in the study, including 38 switched ivermectin and placebo doses, failure of blinding and other considerations, such as the fact that there are widespread over the counter (OTC) ivermectin sales in the same city where the trial site is located. With nearly identical adverse events in both the ivermectin and control groups, just a number of questions mount. Why aren’t the experts out there critiquing this study? Is the Ivermectin finding in this case serving some underlying pecuniary interest? Article 2 | Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p=.002 for effect by state, then 13-fold increase after ivermectin use restricted On May 8, 2020, Peru’s Ministry of Health approved ivermectin (IVM), a drug of Nobel Prize-honored distinction, for inpatient and outpatient treatment of COVID-19. As IVM treatments proceeded in that nation of 33 million residents, excess deaths decreased 14-fold over four months through December 1, 2020, consistent with clinical benefits of IVM for COVID-19 found in several RCTs. But after IVM use was sharply restricted under a new president, excess deaths then increased 13-fold.

A Presentation by Steve Kirsch on how to use VAERS (Vaccine Adverse Event Reporting System) for research.

A follow-up on our story about an 80-year old patient and her family, who had to sue in court to ensure that the patient was given ivermectin as a treatment for COVID-19. The judge ordered that the Millard Fillmore Suburban Hospital allow Mrs. Judith Smentkiewicz to be given ivermectin. The Buffalo News reports that the 80-year old mom is back home “well on the road to recovery.”

TrialSite News founderDaniel O'Connorin conversation about Ivermectin with data analyst Juan Chamie (United States), Dr Pierre Kory (United States) and Prof. Nathi Mdladla (South Africa).

Join The Conversation! | https://trialsitenews.com/ Dr. Vincent Guilamo-Ramos is Dean of the Duke School of Nursing and vice chancellor for nursing affairs, Duke University. He is founder and currently serves as director of Duke's new Center for Latino Adolescent and Family Health. Link to center | https://nursing.duke.edu/news/duson-launches-new-center-focused-latino-adolescent-family-health

Join The Conversation! | https://trialsitenews.com/ Gabriel Nathan is Editor of OC87 Recovery Diaries, suicide prevention advocate, a writer, actor and star of the documentary, A Beautiful Day Tomorrow. A Beautiful Day Tomorrow: Taking Suicide Awareness on the Road – A charming, sweet, human movie about a man and a car, devoted to spreading suicide awareness and prevention everywhere they go. Link | https://abeautifuldaytomorrow.com/

An interview with Dr. Geert Vanden Bossche, a leading virologist and international vaccine expert. Before taking an R&D role for several well-known vaccine companies, he worked for fifteen years in academia. Dr Geert was also the former senior program officer in vaccine discovery for the Bill and Melinda Gates Foundation and the former senior Ebola Program manager for GAVI, Global Alliance for Vaccines and Immunization.

Join The Conversation! | https://trialsitenews.com/ Gabriel Nathan is Editor of OC87 Recovery Diaries, suicide prevention advocate, a writer, actor and star of the documentary, A Beautiful Day Tomorrow. A Beautiful Day Tomorrow: Taking Suicide Awareness on the Road – A charming, sweet, human movie about a man and a car, devoted to spreading suicide awareness and prevention everywhere they go. Link | https://abeautifuldaytomorrow.com/

Join The Conversation! | https://trialsitenews.com/ A Discussion on VAERS & How to Make it Better Dr. Lewin and Dr. Rizk authored a paper on how to improve VAERS. Link | https://pubmed.ncbi.nlm.nih.gov/34400020/ Bio: Dr. Jack Lewin currently heads Lewin and Associates. Prior to this, he was President and CEO of the Cardiovascular Research Foundation and CEO of the American College of Cardiology from 2006-2012. He was also CEO of the California Medical Association for eight years and Hawaii's Director of Heatlh. Dr. Lewin was the founder and first Director of the Navajo National Department of Health and is currently the Chairman of the Board for the National Coalition on Health Care. Dr. John Rizk is a pharmacist and researcher based in Baltimore, Maryland who has several publications related to COVID-19 Link | https://www.researchgate.net/profile/John-Rizk-2

Join The Conversation! | https://trialsitenews.com/ A Discussion on VAERS & How to Make it Better Dr. Lewin and Dr. Rizk authored a paper on how to improve VAERS. Link | https://pubmed.ncbi.nlm.nih.gov/34400020/ Bio: Dr. Jack Lewin currently heads Lewin and Associates. Prior to this, he was President and CEO of the Cardiovascular Research Foundation and CEO of the American College of Cardiology from 2006-2012. He was also CEO of the California Medical Association for eight years and Hawaii's Director of Heatlh. Dr. Lewin was the founder and first Director of the Navajo National Department of Health and is currently the Chairman of the Board for the National Coalition on Health Care. Dr. John Rizk is a pharmacist and researcher based in Baltimore, Maryland who has several publications related to COVID-19 Link | https://www.researchgate.net/profile/John-Rizk-2

Join The Conversation! | https://trialsitenews.com/ Story 1 | Mexico City Wide Innovative Population-Level Study Administers Ivermectin-based Home Kits with Drastic Reduction in Hospitalizations Since December 28, the ivermectin-based medical kits were distributed to mild to moderate symptomatic patients. The Mexico City Government sought to measure the effectiveness o f this population-wide intervention inclusive of the ivermectin-based medical kit in overall hospitalization during the pandemic. Using a quasi-experimental research design involving a Coarsened Exact Matching method leveraging hospital and phone call monitoring data, the study team estimated logistic-regression models with a range of observational data and found a significant reduction in hospitalizations among the cohort receiving ivermectin-based medical kit. Story Article: https://trialsitenews.com/mexico-city-wide-innovative-population-level-study-administers-ivermectin-based-home-kits-with-drastic-reduction-in-hospitalizations/ Story 2 | Uttar Pradesh Health Officials on Record: Claims Ivermectin as Prophylactic Has Lowered COVID-19 Infection Rate & Death Rate The government of Uttar Pradesh, the most populated state in India, has declared that the use of Ivermectin as a “Prophylactic and therapeutic” has not only lowered transmission and infection rates but has also served to reduce the COVID-19 death rate as well. It’s been a year since the first cluster of five (5) cases was reported in Agra, and recently, the Health Department has shared positive results with the ongoing program. TrialSite shared August last year that the most populated Indian state embraced Ivermectin as a COVID-19 therapy and prophylactic while no Western press bothered to touch the subject. More recently, TrialSite reported that ivermectin has been included in the national COVID-19 guidance due in part to positive outcomes now emerging. Again, there hasn’t been a peep from the West. Uttar Pradesh was an early mover, embracing a protocol using both the anti-parasite drug as well as Doxycycline for use as a prophylactic and as a therapeutic tool targeting COVID-19. Clinical trials in Bangladesh using a similar protocol were producing results last summer as well. Now the Uttar Pradesh health department shared recently that it also plans on conducting a controlled study once this second wave of the pandemic wanes. Story Article: https://trialsitenews.com/uttar-pradesh-health-officials-on-record-ivermectin-as-prophylactic-has-lowered-covid-19-infection-rate-death-rates/

Join The Conversation! | https://trialsitenews.com/ A Nurse Shares her experience over losing her job over the Vaccine Mandates. An interview with Dr. Erin. Find us on: Rumble | https://rumble.com/user/TrialSiteNews Odysee | https://odysee.com/@trialsitenews:8

Join The Conversation! | https://trialsitenews.com/ A Nurse Shares her experience over losing her job over the Vaccine Mandates. An interview with Dr. Erin. Find us on: Rumble | https://rumble.com/user/TrialSiteNews Odysee | https://odysee.com/@trialsitenews:8

Join the Conversation! | https://trialsitenews.com/ Mumbai Move for Ivermectin Prophylaxis While Uttar Pradesh Smashes COVID-19: With ivermectin now on the national Indian COVID-19 list of recommended treatments for COVID-19, a few states have gone to the next level and included the low-cost, generic drug approved throughout the world as a parasite fighter as a prophylactic targeting SARS-CoV-2, the virus behind COVID-19. Three Indian states, including Goa, Karnataka and Uttarakhand, have authorized ivermectin as a prophylaxis along with vitamin D during the pandemic. Article Link | https://trialsitenews.com/mumbai-move-for-ivermectin-prophylaxis-while-uttar-pradesh-smashes-covid-19-but-drugs-use-suppressed-in-media/ Indian Bar Association Serves Legal Notice Upon Dr. Soumya Swaminathan, the Chief Scientist, WHO: Dr. Soumya Swaminathan, the Chief Scientist at the World Health Organisation (WHO), was apparently served a legal notice by Indian Bar Association (IBA) on May 25, 2021, for her alleged act of spreading disinformation and thus misleading the people of India, in order to fulfill her own agenda, so the plaintiff’s action declares. Article | https://trialsitenews.com/indian-bar-association-serves-legal-notice-upon-dr-soumya-swaminathan-the-chief-scientist-who/

Join The Conversation! | https://trialsitenews.com/ Jeffrey Klausner, MD, MPH is an infectious disease specialist and professor of medicine in the Division of Infectious Diseases in the David Geffen School of Medicine, as well as Professor of Epidemiology in the Fielding School of Public Health. Dr. Klausner was an Epidemic Intelligence Service Officer at the Centers for Disease Prevention and Control, was a Deputy Health Officer, Director of STD Prevention and Control Services at the San Francisco Department of Public Health and a member of the UCSF School of Medicine faculty. While in San Francisco , he helped identify key factors associated with the increased spread of HIV and STDS and implemented multiple novel public health prevention programs. He helped create the St. James Infirmary, the first occupational health and safety clinic for sex workers and Magnet, a community-based peer-run sexual health clinic for gay men. He also was Branch Chief for HIV and TB at the Centers for Disease Control in Pretoria, South Africa. For Dr. Jeffrey Klausner's Full Bio Click Here | https://chipts.ucla.edu/people/jeffrey-klausner-md-mph/

Join The Conversation! | https://trialsitenews.com/ Jeffrey Klausner, MD, MPH is an infectious disease specialist and professor of medicine in the Division of Infectious Diseases in the David Geffen School of Medicine, as well as Professor of Epidemiology in the Fielding School of Public Health. Dr. Klausner was an Epidemic Intelligence Service Officer at the Centers for Disease Prevention and Control, was a Deputy Health Officer, Director of STD Prevention and Control Services at the San Francisco Department of Public Health and a member of the UCSF School of Medicine faculty. While in San Francisco , he helped identify key factors associated with the increased spread of HIV and STDS and implemented multiple novel public health prevention programs. He helped create the St. James Infirmary, the first occupational health and safety clinic for sex workers and Magnet, a community-based peer-run sexual health clinic for gay men. He also was Branch Chief for HIV and TB at the Centers for Disease Control in Pretoria, South Africa. For Dr. Jeffrey Klausner's Full Bio Click Here | https://chipts.ucla.edu/people/jeffrey-klausner-md-mph/